TABLE 1.
Summary of studies for development of clinical HER-2 target drugs.
| Author/Date | Trial type | Population studies | Number | Methods | Significant | References |
|---|---|---|---|---|---|---|
| Jacquinot et al. (2018) | Prospective study | Patients who received 12 months of trastuzumab | 1631 | LVEF performed every 3 months; every 6 months (patients received trastuzumab and after completion of treatment over the first 2 years) | 48.53% of patients with available measures did not fully recover their baseline LVEF value | Jacquinot et al. (2018) |
| Yoon et al. (2019) | Retrospective study | Patients with trastuzumab-induced left ventricular dysfunction (LVD) | 243 | Major adverse clinical events (MACEs) were compared in non-recovered LVD and recovered LVD. | Non-recovered LVD was associated with MACEs. Decreased LVEF, enlarged LV size, pulmonary hypertension, and anaemia were independent predictors of LV-functional non-recovery | Yoon et al. (2019) |
| Nowsheen et al. (2018) | Retrospective study | Patients with reduced left ventricular ejection fraction during using trastuzumab | 428 | A retrospective study of women treated with trastuzumab for human epidermal growth factor receptor 2 breast cancer at Mayo Clinic Rochester between January 1, 2000 and August 31, 2015 with pre- and on-therapy echocardiograms available for review | Impaired baseline cardiac function experience no higher risk of LVEF decline, but more frequently develop symptomatic heart failure | Nowsheen et al. (2018) |
| Hussain et al. (2019) | Retrospective study | Patients with reduced left ventricular ejection fraction during using trastuzumab | 160 | Retrospectively studied 160 patients with breast cancer receiving trastuzumab in the adjuvant (n = 129) as well as metastatic (n = 31) settings in our institution from 2006 to 2015. During the median follow-up of 3.5 years | Lower LVEF before trastuzumab independently predicted subsequent development of TRC | Hussain et al. (2019) |
| Kaboré et al. (2019) | Prospective study | Patients with stage I–III BC treated with anthracycline and/or trastuzumab | 929 | Analyzed associations between BMI and cardiotoxicity using multivariate logistic regression | The obese group was more prone to cardiotoxicity than the normal-weight group. Obesity and administration of trastuzumab were independently associated with c ardiotoxicity | Kaboré et al. (2019) |
| Keramida et al. (2019) | Prospective study | Patients with consecutive receiving trastuzumab for 12 months | 101 | Comprehensive two-dimensional echocardiography with speckle tracking imaging of LV and RV global longitudinal strain (GLS) and RV free wall longitudinal strain (FWLS) analyses were performed at baseline and every 3 months up to treatment completion | Deformation mechanics of both the left and right ventricle follow similar temporal pattern and degree of impairment, confirming the global and uniform effect of trastuzumab on myocardial function | Keramida et al. (2019) |